{"protocolSection": {"identificationModule": {"nctId": "NCT01644331", "orgStudyIdInfo": {"id": "Pro00037557"}, "organization": {"fullName": "Duke University", "class": "OTHER"}, "briefTitle": "Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure", "officialTitle": "The Targeting Acute Congestion With Tolvaptan In Congestive Heart Failure Study", "acronym": "TACTICS-HF"}, "statusModule": {"statusVerifiedDate": "2017-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-10"}, "primaryCompletionDateStruct": {"date": "2016-02", "type": "ACTUAL"}, "completionDateStruct": {"date": "2016-02", "type": "ACTUAL"}, "studyFirstSubmitDate": "2012-07-17", "studyFirstSubmitQcDate": "2012-07-17", "studyFirstPostDateStruct": {"date": "2012-07-19", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2017-01-06", "resultsFirstSubmitQcDate": "2017-03-17", "resultsFirstPostDateStruct": {"date": "2017-04-27", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2017-03-17", "lastUpdatePostDateStruct": {"date": "2017-04-27", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Duke University", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The primary objective of this study is to compare the effects of oral Tolvaptan vs. placebo as an adjunct to fixed dose IV furosemide on dyspnea relief in patients with acute decompensated heart failure\n\nThe primary hypothesis is that the addition of oral Tolvaptan to fixed dose furosemide will be more effective at relieving dyspnea than fixed dose furosemide alone", "detailedDescription": "This study will be a randomized, double blind, placebo controlled, multi-center clinical trial of patients with signs and symptoms consistent with AHF within 24 hours of presentation at Emergency Department. A total of approximately 250 patients will be enrolled in the trial.\n\nPatients will be randomized in a 1:1 ratio to either of 2 treatment regimens:\n\n* Fixed-dose IV furosemide (1 x total daily oral dose given intravenously in divided doses Q12 hours OR 40 mg IV Q12 hours, whichever is greater) + oral Tolvaptan (given at 0, 24 and 48 hours)\n* Fixed-dose IV furosemide (1 x total daily oral dose given intravenously in divided doses Q12 hours OR 40 mg IV Q12 hours, whichever is greater) + oral placebo (given at 0, 24 and 48 hours)\n\nThe study treatment regimen will be administered from randomization through 48 hours, at which point Tolvaptan/placebo will be discontinued and all diuretic treatment will be adjusted at the treating physician's discretion.\n\nThe primary endpoint will be the proportion of patients with at least moderate improvement in dyspnea by Likert scale at both 8 AND 24 hours AND without the need for escalation of therapy due to worsening heart failure (rescue therapy) or death within 24 hours.\n\nPatients will be followed daily for the duration of hospitalization or for 7 days (whichever is shortest).\n\nAll patients will have Day 30 follow up phone contact for assessment of vital status and interval hospitalizations."}, "conditionsModule": {"conditions": ["Heart Failure", "Dyspnea"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 257, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Tolvaptan", "type": "EXPERIMENTAL", "description": "Fixed-dose IV furosemide (1 x total daily oral dose given intravenously in divided doses Q12 hours OR 40 mg IV Q12 hours, whichever is greater) + oral Tolvaptan (given at 0, 24 and 48 hours)", "interventionNames": ["Drug: Tolvaptan"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Fixed-dose IV furosemide (1 x total daily oral dose given intravenously in divided doses Q12 hours OR 40 mg IV Q12 hours, whichever is greater) + oral placebo (given at 0, 24 and 48 hours)", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Tolvaptan", "description": "IV furosemide plusTolvaptan (given at 0, 24 and 48 hours)", "armGroupLabels": ["Tolvaptan"], "otherNames": ["Samsca"]}, {"type": "DRUG", "name": "Placebo", "description": "IV furosemide plus oral placebo (given at 0, 24 and 48 hours)", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Dyspnea Improvement Measured by Likert Scale at 8 and 24 Hours", "description": "The number of patients with at least moderate improvement (as reported by patient) in dyspnea Likert scale at both 8 AND 24 hours AND without the need for escalation of therapy due to worsening heart failure (rescue therapy) or death within 24 hours.", "timeFrame": "8 and 24 hours"}], "secondaryOutcomes": [{"measure": "Renal Function", "description": "Change in Serum creatinine from baseline to 24, 48 and 72 hours", "timeFrame": "0, 24, 48 and 72 hours"}, {"measure": "Weight Loss", "description": "Change in body weight from baseline to 24, 48, and 72 hours", "timeFrame": "0, 24, 48, and 72 hours"}, {"measure": "Fluid Loss", "description": "Change from baseline fluid balance at 24, 48, and 72 hours", "timeFrame": "0, 24, 48, and 72 hours"}, {"measure": "Dyspnea Likert", "description": "Number of patients that experience moderate or greater improvement (patient reported) in dyspnea by 7 point Likert scale at 48 and 72 hours", "timeFrame": "48 and 72 hours"}, {"measure": "Hospital Stay", "description": "Total days spent in hospital from baseline until discharge or death", "timeFrame": "7 days"}, {"measure": "Worsening or Persistent Heart Failure or Death", "description": "Number of patients with worsening heart failure or death", "timeFrame": "72 hrs"}, {"measure": "Over-diuresis", "description": "clinical evidence of volume depletion requiring intervention other than holding diuretics during the 72 hours after randomization", "timeFrame": "72 hours"}, {"measure": "Serum Sodium", "description": "Change in serum sodium from baseline to 24, 48, and 72 hours", "timeFrame": "0, 24, 48, and 72 hours"}, {"measure": "Dyspnea 11 Point NRS", "description": "Change in NRS for assessment of dyspnea from baseline to 24, 48, and 72 hours (scale ranges from 0-No difficulty breathing to 10-Difficulty as bad as you can imagine)", "timeFrame": "0, 24, 48, and 72 hours"}, {"measure": "Freedom From Congestion", "description": "Jugular Venous Pressure (JVP) \\< 8 cm, no orthopnea, trace peripheral edema or less, and will be assessed at 24, 48, and 72 hours", "timeFrame": "24, 48, and 72 hours"}, {"measure": "Development of Worsening Renal Function", "description": "increase in serum creatinine \u2265 0.3mg/dl from randomization at any time point during 72 hours after randomization", "timeFrame": "72 hours"}, {"measure": "Days Hospitalized or Deceased", "description": "Total days hospitalized or deceased during the 30 days after randomization", "timeFrame": "30 days"}, {"measure": "All Cause Death or Rehospitalization", "description": "All cause death or rehospitalization (to include unscheduled clinic visits or ED visits) at 30 days (Kaplan-Meier and 95% confidence interval)", "timeFrame": "30 days"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* \u2265 18 years of age\n* Daily oral dose of furosemide between \u2265 40 mg(or equivalent)\n* Identified within 24 hours of presentation, defined for purposes of this study as the time of initial dose of intravenous loop diuretic\n* Prior clinical HF diagnosis that was treated with oral loop diuretics for at least 1 month\n* Admission for acute decompensated Heart Failure (HF) as determined by\n\n  * dyspnea at rest or with minimal exertion\n  * Brain Natriuretic Peptide (BNP) \\> 400 or NTproBNP \\> 2000 pg/mL\n\nAND at least one of the following additional signs and symptoms:\n\n* Orthopnea\n* Peripheral edema\n* Elevated JVP (Jugular Venous Pressure)\n* Pulmonary rales\n* Congestion on Chest X-ray\n* No plan for revascularization, cardiac transplant, of ventricular assist device implantation, or other cardiac surgery within 60 days of randomization\n* Signed informed consent\n\nExclusion Criteria:\n\n* Serum Na \\> 140 meq/L\n* Received IV vasoactive treatment or ultra-filtration therapy for HF since initial presentation\n* Treatment plan during current hospitalization includes IV vasoactive treatment or ultra-filtration for HF\n* Systolic Blood Pressure (SBP)\\<90mmHg\n* Serum-Cr\\>3.5mg/dl or currently undergoing renal replacement therapy\n\n  . Known underlying liver disease\n* Hemodynamically significant arrhythmias\n* ACS(Acute coronary syndrome) within 4 weeks prior to study entry\n* Active myocarditis\n* Hypertrophic obstructive, restrictive, constrictive cardiomyopathy\n* Severe stenotic valvular disease\n* Complex congenital heart disease\n* Constrictive pericarditis\n* Clinical evidence of digoxin toxicity\n* Need for mechanical hemodynamic support\n* Terminal illness (other than heart failure) with expected survival time of less than 1 year\n* History of adverse reaction to Tolvaptan\n* Enrollment or planned enrollment in another randomized clinical trial during this hospitalization\n* Pregnant or breast-feeding\n* Inability to comply with planned study procedures", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Michael Felker, MD", "affiliation": "Duke Clinical Research Institute", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "University of Colorado at Denver and Health Sciences Center", "city": "Aurora", "state": "Colorado", "zip": "80045", "country": "United States", "geoPoint": {"lat": 39.72943, "lon": -104.83192}}, {"facility": "Emory University School of Medicine", "city": "Atlanta", "state": "Georgia", "zip": "30322", "country": "United States", "geoPoint": {"lat": 33.749, "lon": -84.38798}}, {"facility": "Northeast Georgia Heart Center", "city": "Gainesville", "state": "Georgia", "zip": "30501", "country": "United States", "geoPoint": {"lat": 34.29788, "lon": -83.82407}}, {"facility": "Mercer University School of Medicine", "city": "Macon", "state": "Georgia", "zip": "31201", "country": "United States", "geoPoint": {"lat": 32.84069, "lon": -83.6324}}, {"facility": "University of Chicago", "city": "Chicago", "state": "Illinois", "zip": "60637", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Indiana University School of Medicine", "city": "Indianapolis", "state": "Indiana", "zip": "46202", "country": "United States", "geoPoint": {"lat": 39.76838, "lon": -86.15804}}, {"facility": "Hennepin County Medical Center", "city": "Minneapolis", "state": "Minnesota", "zip": "55415", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"facility": "Montefiore Medical Center", "city": "Bronx", "state": "New York", "zip": "10461", "country": "United States", "geoPoint": {"lat": 40.84985, "lon": -73.86641}}, {"facility": "University of North Carolina at Chapel Hill", "city": "Chapel Hill", "state": "North Carolina", "zip": "27599", "country": "United States", "geoPoint": {"lat": 35.9132, "lon": -79.05584}}, {"facility": "Novant Health Heart and Vascular", "city": "Charlotte", "state": "North Carolina", "zip": "28204", "country": "United States", "geoPoint": {"lat": 35.22709, "lon": -80.84313}}, {"facility": "Duke University Medical Center", "city": "Durham", "state": "North Carolina", "zip": "27713", "country": "United States", "geoPoint": {"lat": 35.99403, "lon": -78.89862}}, {"facility": "Southeastern Regional Medical Center", "city": "Lumberton", "state": "North Carolina", "zip": "28358", "country": "United States", "geoPoint": {"lat": 34.61834, "lon": -79.01045}}, {"facility": "The Christ Hospital", "city": "Cincinnati", "state": "Ohio", "zip": "45219", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "University of Cincinnati Medical Center", "city": "Cincinnati", "state": "Ohio", "zip": "45267", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Allegheny Valley Hospital", "city": "Natrona Heights", "state": "Pennsylvania", "zip": "15065", "country": "United States", "geoPoint": {"lat": 40.6234, "lon": -79.72977}}, {"facility": "Grand View - Lehigh Valley Health Services", "city": "Sellersville", "state": "Pennsylvania", "zip": "18960", "country": "United States", "geoPoint": {"lat": 40.35399, "lon": -75.3049}}, {"facility": "UT Southwestern Medical center", "city": "Dallas", "state": "Texas", "zip": "75390", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Inova Heart and Vascular Institute", "city": "Falls Church", "state": "Virginia", "zip": "22042", "country": "United States", "geoPoint": {"lat": 38.88233, "lon": -77.17109}}]}, "referencesModule": {"references": [{"pmid": "27654854", "type": "DERIVED", "citation": "Felker GM, Mentz RJ, Cole RT, Adams KF, Egnaczyk GF, Fiuzat M, Patel CB, Echols M, Khouri MG, Tauras JM, Gupta D, Monds P, Roberts R, O'Connor CM. Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure. J Am Coll Cardiol. 2017 Mar 21;69(11):1399-1406. doi: 10.1016/j.jacc.2016.09.004. Epub 2016 Sep 18."}]}, "ipdSharingStatementModule": {"ipdSharing": "UNDECIDED", "description": "Not yet decided."}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Tolvaptan", "description": "IV furosemide (1 x oral dose given IV in Q12 hours divided doses or 40 mg IV Q12 hours, whichever is greater) plus oral Tolvaptan (given at 0, 12, 24 and 48 hours)\n\nTolvaptan: Tolvaptan (given at 0, 12, 24 and 48 hours)"}, {"id": "FG001", "title": "Placebo", "description": "IV furosemide (1 x oral dose given IV Q12 divided doses or 40mg IV Q12 hours, whichever is greater) plus oral placebo (given at O, 24, 48 hours)\n\nPlacebo: IV furosemide (1 x oral dose given IV in Q12 hours divided doses) plus oral placebo (given at 0, 12, 24 and 48 hours)"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "129"}, {"groupId": "FG001", "numSubjects": "128"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "118"}, {"groupId": "FG001", "numSubjects": "118"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "10"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Tolvaptan", "description": "IV furosemide (1 x oral dose given IV in Q12 hours divided doses or 40 mg IV Q12 hours, whichever is greater) plus oral Tolvaptan (given at 0, 12, 24 and 48 hours)\n\nTolvaptan: Tolvaptan (given at 0, 12, 24 and 48 hours)"}, {"id": "BG001", "title": "Placebo", "description": "IV furosemide (1 x oral dose given IV Q12 divided doses or 40mg IV Q12 hours, whichever is greater) plus oral placebo (given at O, 24, 48 hours)\n\nPlacebo: IV furosemide (1 x oral dose given IV in Q12 hours divided doses) plus oral placebo (given at 0, 12, 24 and 48 hours)"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "129"}, {"groupId": "BG001", "value": "128"}, {"groupId": "BG002", "value": "257"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "66.42", "spread": "12.9"}, {"groupId": "BG001", "value": "62.97", "spread": "15.7"}, {"groupId": "BG002", "value": "64.70", "spread": "14.4"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "44"}, {"groupId": "BG001", "value": "42"}, {"groupId": "BG002", "value": "86"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "85"}, {"groupId": "BG001", "value": "86"}, {"groupId": "BG002", "value": "171"}]}]}]}, {"title": "Region of Enrollment", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "129"}, {"groupId": "BG001", "value": "128"}, {"groupId": "BG002", "value": "257"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Dyspnea Improvement Measured by Likert Scale at 8 and 24 Hours", "description": "The number of patients with at least moderate improvement (as reported by patient) in dyspnea Likert scale at both 8 AND 24 hours AND without the need for escalation of therapy due to worsening heart failure (rescue therapy) or death within 24 hours.", "populationDescription": "Baseline population", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "8 and 24 hours", "groups": [{"id": "OG000", "title": "Tolvaptan", "description": "IV furosemide (1 x oral dose given IV in Q12 hours divided doses or 40 mg IV Q12 hours, whichever is greater) plus oral Tolvaptan (given at 0, 12, 24 and 48 hours)\n\nTolvaptan: Tolvaptan (given at 0, 12, 24 and 48 hours)"}, {"id": "OG001", "title": "Placebo", "description": "IV furosemide (1 x oral dose given IV Q12 divided doses or 40mg IV Q12 hours, whichever is greater) plus oral placebo (given at O, 24, 48 hours)\n\nPlacebo: IV furosemide (1 x oral dose given IV in Q12 hours divided doses) plus oral placebo (given at 0, 12, 24 and 48 hours)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "129"}, {"groupId": "OG001", "value": "128"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "26"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.315", "statisticalMethod": "Chi-squared"}]}, {"type": "SECONDARY", "title": "Renal Function", "description": "Change in Serum creatinine from baseline to 24, 48 and 72 hours", "populationDescription": "Baseline population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "0, 24, 48 and 72 hours", "groups": [{"id": "OG000", "title": "Tolvaptan", "description": "IV furosemide (1 x oral dose given IV in Q12 hours divided doses or 40 mg IV Q12 hours, whichever is greater) plus oral Tolvaptan (given at 0, 12, 24 and 48 hours)\n\nTolvaptan: Tolvaptan (given at 0, 12, 24 and 48 hours)"}, {"id": "OG001", "title": "Placebo", "description": "IV furosemide (1 x oral dose given IV Q12 divided doses or 40mg IV Q12 hours, whichever is greater) plus oral placebo (given at O, 24, 48 hours)\n\nPlacebo: IV furosemide (1 x oral dose given IV in Q12 hours divided doses) plus oral placebo (given at 0, 12, 24 and 48 hours)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "129"}, {"groupId": "OG001", "value": "128"}]}], "classes": [{"title": "24 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.13", "spread": "0.4"}, {"groupId": "OG001", "value": "0.04", "spread": "0.3"}]}]}, {"title": "48 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.10", "spread": "0.4"}, {"groupId": "OG001", "value": "0.05", "spread": "0.4"}]}]}, {"title": "72 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.03", "spread": "0.6"}, {"groupId": "OG001", "value": "0.06", "spread": "0.4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "This is a repeated measures analysis so all rows (visits) are taken into account.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.021", "statisticalMethod": "Mixed Models Analysis", "paramType": "Slope", "paramValue": "0.19", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.03", "ciUpperLimit": "0.34"}]}, {"type": "SECONDARY", "title": "Weight Loss", "description": "Change in body weight from baseline to 24, 48, and 72 hours", "populationDescription": "Baseline population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "lbs", "timeFrame": "0, 24, 48, and 72 hours", "groups": [{"id": "OG000", "title": "Tolvaptan", "description": "IV furosemide (1 x oral dose given IV in Q12 hours divided doses or 40 mg IV Q12 hours, whichever is greater) plus oral Tolvaptan (given at 0, 12, 24 and 48 hours)\n\nTolvaptan: Tolvaptan (given at 0, 12, 24 and 48 hours)"}, {"id": "OG001", "title": "Placebo", "description": "IV furosemide (1 x oral dose given IV Q12 divided doses or 40mg IV Q12 hours, whichever is greater) plus oral placebo (given at O, 24, 48 hours)\n\nPlacebo: IV furosemide (1 x oral dose given IV in Q12 hours divided doses) plus oral placebo (given at 0, 12, 24 and 48 hours)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "129"}, {"groupId": "OG001", "value": "128"}]}], "classes": [{"title": "24 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.41", "spread": "6.6"}, {"groupId": "OG001", "value": "-1.16", "spread": "13.2"}]}]}, {"title": "48 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "-6.11", "spread": "7.4"}, {"groupId": "OG001", "value": "-3.46", "spread": "6.3"}]}]}, {"title": "72 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "-8.19", "spread": "9.7"}, {"groupId": "OG001", "value": "-5.53", "spread": "7.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "This a repeated measure analysis so all rows (visits) are taken into account.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.430", "statisticalMethod": "Mixed Models Analysis", "paramType": "Slope", "paramValue": "0.99", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.47", "ciUpperLimit": "3.44"}]}, {"type": "SECONDARY", "title": "Fluid Loss", "description": "Change from baseline fluid balance at 24, 48, and 72 hours", "populationDescription": "baseline population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mL", "timeFrame": "0, 24, 48, and 72 hours", "groups": [{"id": "OG000", "title": "Tolvaptan", "description": "IV furosemide (1 x oral dose given IV in Q12 hours divided doses or 40 mg IV Q12 hours, whichever is greater) plus oral Tolvaptan (given at 0, 12, 24 and 48 hours)\n\nTolvaptan: Tolvaptan (given at 0, 12, 24 and 48 hours)"}, {"id": "OG001", "title": "Placebo", "description": "IV furosemide (1 x oral dose given IV Q12 divided doses or 40mg IV Q12 hours, whichever is greater) plus oral placebo (given at O, 24, 48 hours)\n\nPlacebo: IV furosemide (1 x oral dose given IV in Q12 hours divided doses) plus oral placebo (given at 0, 12, 24 and 48 hours)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "129"}, {"groupId": "OG001", "value": "128"}]}], "classes": [{"title": "24 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2182.25", "spread": "1844.4"}, {"groupId": "OG001", "value": "-1541.48", "spread": "1524.5"}]}]}, {"title": "48 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1948.01", "spread": "1635.6"}, {"groupId": "OG001", "value": "-1419.09", "spread": "1378.6"}]}]}, {"title": "72 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1757.09", "spread": "1670.4"}, {"groupId": "OG001", "value": "-1401.24", "spread": "1386.5"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "This is a repeated measures analysis so all rows (visits) are taken into account.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.157", "statisticalMethod": "Mixed Models Analysis", "paramType": "Slope", "paramValue": "-493.21", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1176.96", "ciUpperLimit": "190.55"}]}, {"type": "SECONDARY", "title": "Dyspnea Likert", "description": "Number of patients that experience moderate or greater improvement (patient reported) in dyspnea by 7 point Likert scale at 48 and 72 hours", "populationDescription": "baseline population", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "48 and 72 hours", "groups": [{"id": "OG000", "title": "Tolvaptan", "description": "IV furosemide (1 x oral dose given IV in Q12 hours divided doses or 40 mg IV Q12 hours, whichever is greater) plus oral Tolvaptan (given at 0, 12, 24 and 48 hours)\n\nTolvaptan: Tolvaptan (given at 0, 12, 24 and 48 hours)"}, {"id": "OG001", "title": "Placebo", "description": "IV furosemide (1 x oral dose given IV Q12 divided doses or 40mg IV Q12 hours, whichever is greater) plus oral placebo (given at O, 24, 48 hours)\n\nPlacebo: IV furosemide (1 x oral dose given IV in Q12 hours divided doses) plus oral placebo (given at 0, 12, 24 and 48 hours)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "129"}, {"groupId": "OG001", "value": "128"}]}], "classes": [{"title": "48 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "88"}, {"groupId": "OG001", "value": "74"}]}]}, {"title": "72 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "69"}, {"groupId": "OG001", "value": "48"}]}]}], "analyses": [{"groupIds": ["OG001"], "groupDescription": "This is a repeated measures analysis so all rows (visits) are taken into account.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.206", "statisticalMethod": "Chi-squared"}]}, {"type": "SECONDARY", "title": "Hospital Stay", "description": "Total days spent in hospital from baseline until discharge or death", "populationDescription": "baseline population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "days", "timeFrame": "7 days", "groups": [{"id": "OG000", "title": "Tolvaptan", "description": "IV furosemide (1 x oral dose given IV in Q12 hours divided doses or 40 mg IV Q12 hours, whichever is greater) plus oral Tolvaptan (given at 0, 12, 24 and 48 hours)\n\nTolvaptan: Tolvaptan (given at 0, 12, 24 and 48 hours)"}, {"id": "OG001", "title": "Placebo", "description": "IV furosemide (1 x oral dose given IV Q12 divided doses or 40mg IV Q12 hours, whichever is greater) plus oral placebo (given at O, 24, 48 hours)\n\nPlacebo: IV furosemide (1 x oral dose given IV in Q12 hours divided doses) plus oral placebo (given at 0, 12, 24 and 48 hours)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "129"}, {"groupId": "OG001", "value": "128"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "6.46", "spread": "5.9"}, {"groupId": "OG001", "value": "7.35", "spread": "7.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.334", "statisticalMethod": "Log Rank", "paramType": "Kaplan Meier", "paramValue": "0.98", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.96", "ciUpperLimit": "0.99"}]}, {"type": "SECONDARY", "title": "Worsening or Persistent Heart Failure or Death", "description": "Number of patients with worsening heart failure or death", "populationDescription": "baseline population", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "72 hrs", "groups": [{"id": "OG000", "title": "Tolvaptan", "description": "IV furosemide (1 x oral dose given IV in Q12 hours divided doses or 40 mg IV Q12 hours, whichever is greater) plus oral Tolvaptan (given at 0, 12, 24 and 48 hours)\n\nTolvaptan: Tolvaptan (given at 0, 12, 24 and 48 hours)"}, {"id": "OG001", "title": "Placebo", "description": "IV furosemide (1 x oral dose given IV Q12 divided doses or 40mg IV Q12 hours, whichever is greater) plus oral placebo (given at O, 24, 48 hours)\n\nPlacebo: IV furosemide (1 x oral dose given IV in Q12 hours divided doses) plus oral placebo (given at 0, 12, 24 and 48 hours)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "129"}, {"groupId": "OG001", "value": "128"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "60"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.148", "statisticalMethod": "Chi-squared"}]}, {"type": "SECONDARY", "title": "Over-diuresis", "description": "clinical evidence of volume depletion requiring intervention other than holding diuretics during the 72 hours after randomization", "populationDescription": "baseline population", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "72 hours", "groups": [{"id": "OG000", "title": "Tolvaptan", "description": "IV furosemide (1 x oral dose given IV in Q12 hours divided doses or 40 mg IV Q12 hours, whichever is greater) plus oral Tolvaptan (given at 0, 12, 24 and 48 hours)\n\nTolvaptan: Tolvaptan (given at 0, 12, 24 and 48 hours)"}, {"id": "OG001", "title": "Placebo", "description": "IV furosemide (1 x oral dose given IV Q12 divided doses or 40mg IV Q12 hours, whichever is greater) plus oral placebo (given at O, 24, 48 hours)\n\nPlacebo: IV furosemide (1 x oral dose given IV in Q12 hours divided doses) plus oral placebo (given at 0, 12, 24 and 48 hours)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "129"}, {"groupId": "OG001", "value": "128"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.334", "statisticalMethod": "Chi-squared"}]}, {"type": "SECONDARY", "title": "Serum Sodium", "description": "Change in serum sodium from baseline to 24, 48, and 72 hours", "populationDescription": "baseline population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "0, 24, 48, and 72 hours", "groups": [{"id": "OG000", "title": "Tolvaptan", "description": "IV furosemide (1 x oral dose given IV in Q12 hours divided doses or 40 mg IV Q12 hours, whichever is greater) plus oral Tolvaptan (given at 0, 12, 24 and 48 hours)\n\nTolvaptan: Tolvaptan (given at 0, 12, 24 and 48 hours)"}, {"id": "OG001", "title": "Placebo", "description": "IV furosemide (1 x oral dose given IV Q12 divided doses or 40mg IV Q12 hours, whichever is greater) plus oral placebo (given at O, 24, 48 hours)\n\nPlacebo: IV furosemide (1 x oral dose given IV in Q12 hours divided doses) plus oral placebo (given at 0, 12, 24 and 48 hours)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "129"}, {"groupId": "OG001", "value": "128"}]}], "classes": [{"title": "24 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.18", "spread": "3.3"}, {"groupId": "OG001", "value": "0.23", "spread": "2.5"}]}]}, {"title": "48 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.34", "spread": "3.7"}, {"groupId": "OG001", "value": "-0.24", "spread": "2.8"}]}]}, {"title": "72 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.84", "spread": "3.9"}, {"groupId": "OG001", "value": "-0.44", "spread": "2.9"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "This is a repeated measures analysis so all rows (visits) are taken into account.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.241", "statisticalMethod": "Mixed Models Analysis", "paramType": "Slope", "paramValue": "-0.67", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.79", "ciUpperLimit": "0.45"}]}, {"type": "SECONDARY", "title": "Dyspnea 11 Point NRS", "description": "Change in NRS for assessment of dyspnea from baseline to 24, 48, and 72 hours (scale ranges from 0-No difficulty breathing to 10-Difficulty as bad as you can imagine)", "populationDescription": "baseline population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "0, 24, 48, and 72 hours", "groups": [{"id": "OG000", "title": "Tolvaptan", "description": "IV furosemide (1 x oral dose given IV in Q12 hours divided doses or 40 mg IV Q12 hours, whichever is greater) plus oral Tolvaptan (given at 0, 12, 24 and 48 hours)\n\nTolvaptan: Tolvaptan (given at 0, 12, 24 and 48 hours)"}, {"id": "OG001", "title": "Placebo", "description": "IV furosemide (1 x oral dose given IV Q12 divided doses or 40mg IV Q12 hours, whichever is greater) plus oral placebo (given at O, 24, 48 hours)\n\nPlacebo: IV furosemide (1 x oral dose given IV in Q12 hours divided doses) plus oral placebo (given at 0, 12, 24 and 48 hours)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "129"}, {"groupId": "OG001", "value": "128"}]}], "classes": [{"title": "24 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.20", "spread": "2.5"}, {"groupId": "OG001", "value": "-1.84", "spread": "2.1"}]}]}, {"title": "48 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.85", "spread": "2.7"}, {"groupId": "OG001", "value": "-2.29", "spread": "2.3"}]}]}, {"title": "72 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.07", "spread": "3.0"}, {"groupId": "OG001", "value": "-2.42", "spread": "2.4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "This is a repeated measures analysis so all rows (visits) are taken into account.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.303", "statisticalMethod": "Mixed Models Analysis", "paramType": "Slope", "paramValue": "0.28", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.26", "ciUpperLimit": "0.82"}]}, {"type": "SECONDARY", "title": "Freedom From Congestion", "description": "Jugular Venous Pressure (JVP) \\< 8 cm, no orthopnea, trace peripheral edema or less, and will be assessed at 24, 48, and 72 hours", "populationDescription": "baseline population", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "24, 48, and 72 hours", "groups": [{"id": "OG000", "title": "Tolvaptan", "description": "IV furosemide (1 x oral dose given IV in Q12 hours divided doses or 40 mg IV Q12 hours, whichever is greater) plus oral Tolvaptan (given at 0, 12, 24 and 48 hours)\n\nTolvaptan: Tolvaptan (given at 0, 12, 24 and 48 hours)"}, {"id": "OG001", "title": "Placebo", "description": "IV furosemide (1 x oral dose given IV Q12 divided doses or 40mg IV Q12 hours, whichever is greater) plus oral placebo (given at O, 24, 48 hours)\n\nPlacebo: IV furosemide (1 x oral dose given IV in Q12 hours divided doses) plus oral placebo (given at 0, 12, 24 and 48 hours)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "129"}, {"groupId": "OG001", "value": "128"}]}], "classes": [{"title": "24 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "12"}]}]}, {"title": "48 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "20"}]}]}, {"title": "72 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "17"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.471", "pValueComment": "24 hours", "statisticalMethod": "Chi-squared"}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.585", "pValueComment": "48 hrs", "statisticalMethod": "Chi-squared"}, {"groupIds": ["OG000"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.120", "pValueComment": "72 hrs", "statisticalMethod": "Chi-squared"}]}, {"type": "SECONDARY", "title": "Development of Worsening Renal Function", "description": "increase in serum creatinine \u2265 0.3mg/dl from randomization at any time point during 72 hours after randomization", "populationDescription": "baseline population", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "72 hours", "groups": [{"id": "OG000", "title": "Tolvaptan", "description": "IV furosemide (1 x oral dose given IV in Q12 hours divided doses or 40 mg IV Q12 hours, whichever is greater) plus oral Tolvaptan (given at 0, 12, 24 and 48 hours)\n\nTolvaptan: Tolvaptan (given at 0, 12, 24 and 48 hours)"}, {"id": "OG001", "title": "Placebo", "description": "IV furosemide (1 x oral dose given IV Q12 divided doses or 40mg IV Q12 hours, whichever is greater) plus oral placebo (given at O, 24, 48 hours)\n\nPlacebo: IV furosemide (1 x oral dose given IV in Q12 hours divided doses) plus oral placebo (given at 0, 12, 24 and 48 hours)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "129"}, {"groupId": "OG001", "value": "128"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "34"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.037", "statisticalMethod": "Chi-squared"}]}, {"type": "SECONDARY", "title": "Days Hospitalized or Deceased", "description": "Total days hospitalized or deceased during the 30 days after randomization", "populationDescription": "baseline population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "days", "timeFrame": "30 days", "groups": [{"id": "OG000", "title": "Tolvaptan", "description": "IV furosemide (1 x oral dose given IV in Q12 hours divided doses or 40 mg IV Q12 hours, whichever is greater) plus oral Tolvaptan (given at 0, 12, 24 and 48 hours)\n\nTolvaptan: Tolvaptan (given at 0, 12, 24 and 48 hours)"}, {"id": "OG001", "title": "Placebo", "description": "IV furosemide (1 x oral dose given IV Q12 divided doses or 40mg IV Q12 hours, whichever is greater) plus oral placebo (given at O, 24, 48 hours)\n\nPlacebo: IV furosemide (1 x oral dose given IV in Q12 hours divided doses) plus oral placebo (given at 0, 12, 24 and 48 hours)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "129"}, {"groupId": "OG001", "value": "128"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "10.19", "spread": "10.9"}, {"groupId": "OG001", "value": "11.69", "spread": "11.7"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.373", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}]}, {"type": "SECONDARY", "title": "All Cause Death or Rehospitalization", "description": "All cause death or rehospitalization (to include unscheduled clinic visits or ED visits) at 30 days (Kaplan-Meier and 95% confidence interval)", "populationDescription": "baseline population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "proportion of participants", "timeFrame": "30 days", "groups": [{"id": "OG000", "title": "Tolvaptan", "description": "IV furosemide (1 x oral dose given IV in Q12 hours divided doses or 40 mg IV Q12 hours, whichever is greater) plus oral Tolvaptan (given at 0, 12, 24 and 48 hours)\n\nTolvaptan: Tolvaptan (given at 0, 12, 24 and 48 hours)"}, {"id": "OG001", "title": "Placebo", "description": "IV furosemide (1 x oral dose given IV Q12 divided doses or 40mg IV Q12 hours, whichever is greater) plus oral placebo (given at O, 24, 48 hours)\n\nPlacebo: IV furosemide (1 x oral dose given IV in Q12 hours divided doses) plus oral placebo (given at 0, 12, 24 and 48 hours)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "129"}, {"groupId": "OG001", "value": "128"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.33", "lowerLimit": "0.25", "upperLimit": "0.42"}, {"groupId": "OG001", "value": "0.29", "lowerLimit": "0.22", "upperLimit": "0.38"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.709", "statisticalMethod": "Log Rank", "paramType": "Kaplan Meier", "paramValue": "0.26", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.21", "ciUpperLimit": "0.32"}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Serious adverse events occurring from randomization through day 7 or discharge (whichever occurred first)", "eventGroups": [{"id": "EG000", "title": "Tolvaptan", "description": "IV furosemide (1 x oral dose given IV in Q12 hours divided doses or 40 mg IV Q12 hours, whichever is greater) plus oral Tolvaptan (given at 0, 12, 24 and 48 hours)\n\nTolvaptan: Tolvaptan (given at 0, 12, 24 and 48 hours)", "seriousNumAffected": 8, "seriousNumAtRisk": 129, "otherNumAffected": 101, "otherNumAtRisk": 129}, {"id": "EG001", "title": "Placebo", "description": "IV furosemide (1 x oral dose given IV Q12 divided doses or 40mg IV Q12 hours, whichever is greater) plus oral placebo (given at O, 24, 48 hours)\n\nPlacebo: IV furosemide (1 x oral dose given IV in Q12 hours divided doses) plus oral placebo (given at 0, 12, 24 and 48 hours)", "seriousNumAffected": 2, "seriousNumAtRisk": 128, "otherNumAffected": 107, "otherNumAtRisk": 128}], "seriousEvents": [{"term": "Blood Sodium Increase", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 129}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 128}]}, {"term": "Epistaxis", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 129}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 128}]}, {"term": "Cerebrovascular Accident", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 129}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 128}]}, {"term": "Hypotension", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 129}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 128}]}, {"term": "Cardiogenic Shock", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 129}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 128}]}, {"term": "Uterine Cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 129}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 128}]}, {"term": "Chronic Obstructive Pulmonary Disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 129}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 128}]}, {"term": "Sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 129}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 128}]}, {"term": "Hyponatraemia", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 129}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 128}]}], "otherEvents": [{"term": "Atrial Fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 13, "numAffected": 13, "numAtRisk": 129}, {"groupId": "EG001", "numEvents": 19, "numAffected": 19, "numAtRisk": 128}]}, {"term": "Ventricular Tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 129}, {"groupId": "EG001", "numEvents": 7, "numAffected": 7, "numAtRisk": 128}]}, {"term": "Myocardial Infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 129}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 128}]}, {"term": "Acute Coronary Syndrome", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 129}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 128}]}, {"term": "Acute Renal Failure", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 24, "numAffected": 24, "numAtRisk": 129}, {"groupId": "EG001", "numEvents": 15, "numAffected": 15, "numAtRisk": 128}]}, {"term": "Worsening Heart Failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 86, "numAffected": 49, "numAtRisk": 129}, {"groupId": "EG001", "numEvents": 106, "numAffected": 59, "numAtRisk": 128}]}, {"term": "Death", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 8, "numAtRisk": 129}, {"groupId": "EG001", "numEvents": 7, "numAffected": 7, "numAtRisk": 128}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "GT60", "restrictiveAgreement": true}, "pointOfContact": {"title": "G. Michael Felker, MD", "organization": "Duke Clinical Research Institute", "email": "Michael.Felker@duke.edu", "phone": "919-668-8919"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000004417", "term": "Dyspnea"}, {"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000012120", "term": "Respiration Disorders"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000012818", "term": "Signs and Symptoms, Respiratory"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M7591", "name": "Dyspnea", "asFound": "Dyspnea", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "M14957", "name": "Respiration Disorders", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M15623", "name": "Signs and Symptoms, Respiratory", "relevance": "LOW"}, {"id": "T170", "name": "Acute Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000077602", "term": "Tolvaptan"}], "ancestors": [{"id": "D000065092", "term": "Antidiuretic Hormone Receptor Antagonists"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M8784", "name": "Furosemide", "relevance": "LOW"}, {"id": "M1858", "name": "Tolvaptan", "asFound": "Total volume", "relevance": "HIGH"}, {"id": "M17414", "name": "Vasopressins", "relevance": "LOW"}, {"id": "M4437", "name": "Arginine Vasopressin", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}], "browseBranches": [{"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}, {"abbrev": "Coag", "name": "Coagulants"}]}}, "hasResults": true}